[go: up one dir, main page]

WO2008097461A3 - Hepcidine, antagonistes de l'hepcidine, et procédés d'utilisation - Google Patents

Hepcidine, antagonistes de l'hepcidine, et procédés d'utilisation Download PDF

Info

Publication number
WO2008097461A3
WO2008097461A3 PCT/US2008/001325 US2008001325W WO2008097461A3 WO 2008097461 A3 WO2008097461 A3 WO 2008097461A3 US 2008001325 W US2008001325 W US 2008001325W WO 2008097461 A3 WO2008097461 A3 WO 2008097461A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepcidin
antibodies
methods
purified
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/001325
Other languages
English (en)
Other versions
WO2008097461A2 (fr
Inventor
Barbra Sasu
Mitsuru Haniu
Thomas Charles Boone
Xiao-Juan Bi
Ki Jeong Lee
Tara Arvedson
Aaron Winters
Keegan Cooke
Zeqi Sheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39682290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008097461(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to MX2009008104A priority Critical patent/MX2009008104A/es
Priority to CA002676036A priority patent/CA2676036A1/fr
Priority to JP2009548312A priority patent/JP2010517529A/ja
Priority to EP08725041A priority patent/EP2111412A2/fr
Priority to AU2008214386A priority patent/AU2008214386B2/en
Publication of WO2008097461A2 publication Critical patent/WO2008097461A2/fr
Publication of WO2008097461A3 publication Critical patent/WO2008097461A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)

Abstract

L'invention concerne l'hepcidine purifiée et correctement repliée, des anticorps qui se lient à l'hepcidine, et des procédés de fabrication et d'utilisation de telles substances. L'invention concerne également des procédés de traitement de troubles liés à l'hepcidine.
PCT/US2008/001325 2007-02-02 2008-01-30 Hepcidine, antagonistes de l'hepcidine, et procédés d'utilisation Ceased WO2008097461A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2009008104A MX2009008104A (es) 2007-02-02 2008-01-30 Hepcidina, antagonistas de hepcidina y metodos de uso.
CA002676036A CA2676036A1 (fr) 2007-02-02 2008-01-30 Hepcidine, antagonistes de l'hepcidine, et procedes d'utilisation
JP2009548312A JP2010517529A (ja) 2007-02-02 2008-01-30 ヘプシジン及びヘプシジン抗体
EP08725041A EP2111412A2 (fr) 2007-02-02 2008-01-30 Hepcidine, antagonistes de l'hepcidine, et procédés d'utilisation
AU2008214386A AU2008214386B2 (en) 2007-02-02 2008-01-30 Hepcidin and hepcidin antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88805907P 2007-02-02 2007-02-02
US60/888,059 2007-02-02
US1513807P 2007-12-19 2007-12-19
US61/015,138 2007-12-19

Publications (2)

Publication Number Publication Date
WO2008097461A2 WO2008097461A2 (fr) 2008-08-14
WO2008097461A3 true WO2008097461A3 (fr) 2009-05-14

Family

ID=39682290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/001325 Ceased WO2008097461A2 (fr) 2007-02-02 2008-01-30 Hepcidine, antagonistes de l'hepcidine, et procédés d'utilisation

Country Status (11)

Country Link
US (3) US8629250B2 (fr)
EP (1) EP2111412A2 (fr)
JP (2) JP2010517529A (fr)
AR (2) AR065083A1 (fr)
AU (1) AU2008214386B2 (fr)
CA (1) CA2676036A1 (fr)
CL (1) CL2008000278A1 (fr)
MX (1) MX2009008104A (fr)
PE (2) PE20130588A1 (fr)
TW (3) TW200900420A (fr)
WO (1) WO2008097461A2 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4944360B2 (ja) 2001-05-25 2012-05-30 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
WO2008036933A2 (fr) 2006-09-21 2008-03-27 Alnylam Pharmaceuticals, Inc. Compositions et procédés servant à inhiber l'expression du gène hamp
CN101903044A (zh) 2007-10-02 2010-12-01 国家健康与医学研究院 对人铁调素具有特异性的抗原结合蛋白
AR069062A1 (es) * 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
US9175078B2 (en) * 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
EP2620448A1 (fr) * 2008-05-01 2013-07-31 Amgen Inc. Anticorps anti-hepcidine et méthodes d'utilisation associées
KR101462307B1 (ko) 2008-08-06 2014-11-17 일라이 릴리 앤드 캄파니 항-헵시딘-25 선택적 항체 및 그의 용도
EP2157432A1 (fr) * 2008-08-15 2010-02-24 Qiagen GmbH Procédé d'analyse d'un échantillon complexe par spectrométrie de masse
US8435941B2 (en) 2008-12-05 2013-05-07 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
US8183346B2 (en) 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
US8999935B2 (en) * 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
MX2011013898A (es) 2009-06-22 2012-05-22 Amgen Inc Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
US8940878B2 (en) 2009-06-25 2015-01-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
US9395370B2 (en) * 2009-07-08 2016-07-19 Bio-Rad Laboratories, Inc. Purification of monoclonal antibodies
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
WO2011020886A1 (fr) 2009-08-20 2011-02-24 Vifor (International) Ag Nouveaux antagonistes de chinoline-hepcidine
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
JP2013503835A (ja) 2009-09-07 2013-02-04 ヴィフォール （インターナショナル） アクチェンゲゼルシャフト 新規なエタンジアミン系ヘプシジン拮抗薬
TW201111379A (en) 2009-09-09 2011-04-01 Vifor Int Ag Novel thiazole-and oxazole-hepcidine-antagonists
WO2011057744A1 (fr) 2009-11-13 2011-05-19 Roche Diagnostics Gmbh Diagnostic différentiel de carences en fer sur la base de l'hepcidine et de la concentration moyenne en hémoglobine par réticulocyte
WO2011071368A1 (fr) 2009-12-11 2011-06-16 Umc St. Radboud Méthode de mesure de l'hepcidine
CN101955525B (zh) * 2010-07-13 2012-11-07 中国农业科学院兰州畜牧与兽药研究所 一种人工抗菌肽及其基因与制备方法
DK2606061T3 (da) 2010-08-16 2017-11-06 Pieris Pharmaceuticals Gmbh Bindingsproteiner til hepcidin
US20140057970A1 (en) * 2010-10-29 2014-02-27 Frank Schwobel Use of Hepcidin Binding Nucleic Acids for Depletion of Hepcidin From the Body
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
WO2012122025A2 (fr) 2011-03-04 2012-09-13 Intrexon Corporation Vecteurs exprimant une protéine de façon conditionnelle
US9228188B2 (en) 2011-06-21 2016-01-05 Alnylam Pharmaceuticals, Inc. Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
EP2723865B1 (fr) * 2011-06-21 2019-03-27 Alnylam Pharmaceuticals, Inc. PROCÉDÉS DE DÉTERMINATION DE L'ACTIVITÉ DU RNAi CHEZ UN SUJET
US20130012429A1 (en) * 2011-07-06 2013-01-10 Lucy Ann Eddowes Anti-viral therapy
EP2788370B1 (fr) * 2011-12-09 2020-02-05 The Regents of The University of California Peptides mini-hepcidine modifiés et leurs procédés d'utilisation
AU2012350654C1 (en) 2011-12-12 2018-05-10 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
US10457733B2 (en) * 2012-08-03 2019-10-29 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
RU2684216C2 (ru) * 2012-11-01 2019-04-04 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Эритроферрон и erfe-полипептиды и способы регуляции метаболизма железа
JP6463331B2 (ja) * 2013-03-15 2019-01-30 イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー 抗ヘプシジン抗体およびその使用
PL2968443T3 (pl) 2013-03-15 2022-02-07 Protagonist Therapeutics, Inc. Analogi hepcydyny i ich zastosowania
JP6469644B2 (ja) * 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
CA2932548C (fr) 2014-01-30 2020-10-27 F. Hoffmann-La Roche Ag Stabilisation de sang total a temperature ambiante
US9315545B2 (en) 2014-04-07 2016-04-19 Merganser Biotech, Inc. Hepcidin mimetic peptides and uses thereof
CN113621027A (zh) 2014-05-16 2021-11-09 领导医疗有限公司 α4β7整联蛋白硫醚肽拮抗剂
AU2015279571A1 (en) * 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AU2015328002A1 (en) 2014-10-01 2017-04-27 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
WO2016146587A1 (fr) 2015-03-13 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes de l'hepcidine destinés à être utilisés dans le traitement de l'inflammation
CN108271422A (zh) 2015-06-25 2018-07-10 株式会社国际电气通信基础技术研究所 基于器官间串扰系统的预测装置及预测程序
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20170029499A1 (en) * 2015-07-31 2017-02-02 Astrazeneca Pharmaceuticals Lp Methods for treating hepcidin-mediated disorders
EP3344287B1 (fr) 2015-09-04 2021-05-26 Health Research, Inc. Anticorps anti-survivine pour le traitement du cancer
CA3009834A1 (fr) * 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree
EP3432906A4 (fr) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. Procédés de synthèse d'antagonistes de peptide alpha4beta7
JP6332780B2 (ja) 2016-03-29 2018-05-30 株式会社国際電気通信基礎技術研究所 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法
WO2017170610A1 (fr) * 2016-03-29 2017-10-05 株式会社国際電気通信基礎技術研究所 Procédé de criblage de substances candidates pour un composant actif pour prévenir ou traiter au moins une maladie choisie dans le groupe constitué d'une hypofonction rénale, une maladie rénale chronique et une insuffisance rénale
US10347656B2 (en) * 2016-07-18 2019-07-09 Semiconductor Components Industries, Llc Semiconductor device and monolithic semiconductor device including a power semiconductor device and a control circuit
WO2018027184A1 (fr) * 2016-08-05 2018-02-08 Silarus Therapeutics, Inc. Compositions d'anticorps spécifiques d'erfe et procédés d'utilisation
WO2018053468A1 (fr) * 2016-09-19 2018-03-22 The University Of Toledo Anticorps igm monoclonaux produits à partir de constructions entièrement glucidiques
WO2018234538A1 (fr) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagoniste ou agoniste d'hepcidine destiné à être utilisé dans le traitement d'une dysrégulation du métabolisme du mo et/ou du mn
TW201920234A (zh) 2017-09-11 2019-06-01 美商領導醫療有限公司 類鴉片促效劑肽及其用途
WO2019157268A1 (fr) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Mimétiques d'hepcidine conjugués
EP3805757A4 (fr) * 2018-06-04 2022-03-23 Chugai Seiyaku Kabushiki Kaisha Procédé permettant de détecter un complexe
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
US11725058B2 (en) * 2019-06-26 2023-08-15 Ap Biosciences, Inc. CD137 antibodies for T-cell activation
JP7534382B2 (ja) 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
JP2022549506A (ja) * 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
WO2021062171A1 (fr) * 2019-09-27 2021-04-01 Disc Medicine, Inc. Méthodes de traitement de l'anémie des maladies chroniques
EP4090669A4 (fr) 2020-01-15 2024-11-20 Janssen Biotech, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
EP4103595A4 (fr) * 2020-02-11 2024-06-26 Quest Diagnostics Investments LLC Système de détermination d'une cause sous-jacente de l'anémie
WO2021207072A1 (fr) * 2020-04-07 2021-10-14 Mabwell Therapeutics Inc. Anticorps anti-tmprss6 et leurs utilisations
EP4149548A4 (fr) 2020-05-13 2024-05-08 Disc Medicine, Inc. Anticorps anti-hémojuvéline (hjv) pour le traitement de la myélofibrose
WO2022098812A1 (fr) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Méthodes de traitement d'une surcharge en fer
EP4247403A4 (fr) 2020-11-20 2024-12-11 JANSSEN Pharmaceutica NV Compositions d'inhibiteurs peptidiques du récepteur de l'interleukine-23
JPWO2022154121A1 (fr) * 2021-01-18 2022-07-21
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
CN115356414B (zh) * 2022-08-19 2024-11-29 珠海市丽珠单抗生物技术有限公司 糖蛋白二硫键的鉴定方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098444A2 (fr) * 2001-05-25 2002-12-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de l'hepcidine comme regulateur de l'homeostasie ferrique
WO2004058044A2 (fr) * 2002-11-19 2004-07-15 Drg International, Inc. Methode diagnostique pour maladies par criblage d'hepcidine dans des tissus, du sang ou des fluides corporels humains ou animaux et utilisations therapeutiques
WO2004106362A2 (fr) * 2003-05-30 2004-12-09 Cellpep S.A. Oxydation de peptides
US20060019339A1 (en) * 2004-04-28 2006-01-26 Xavier Lauth Measurement of bioactive hepcidins
WO2006099126A2 (fr) * 2005-03-11 2006-09-21 Ciphergen Biosystems, Inc. Biomarqueurs du cancer de l'ovaire et de l'endometre: la hepcidine
WO2008089795A1 (fr) * 2007-01-25 2008-07-31 Drg International, Inc. Procédé de diagnostic de maladies par dépistage de l'hepcidine dans des tissus, du sang ou des liquides organiques humains ou animaux, anticorps monoclonaux spécifiques de l'hepcidine humaine et leurs utilisations associées

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
USRE30985E (en) * 1978-01-01 1982-06-29 Serum-free cell culture media
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4452901A (en) * 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (fr) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Composition à action prolongée
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) * 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5244805A (en) 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US7217689B1 (en) * 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5885527A (en) * 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5807549A (en) * 1993-05-21 1998-09-15 Research Corporation Technologies, Inc. Lymphocyte chemoattractant factor and uses thereof
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US6054287A (en) * 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5723750A (en) * 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO1997014719A1 (fr) 1995-10-16 1997-04-24 Unilever N.V. Analogue de fragment d'anticorps bifonctionnel ou bivalent
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6278039B1 (en) 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
KR100641969B1 (ko) * 1997-07-23 2006-11-06 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의한 에리트로포이에틴의제조방법
US20030044772A1 (en) * 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6251588B1 (en) * 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6310078B1 (en) * 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
AU775422B2 (en) 1998-06-15 2004-07-29 Gtc Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US6210924B1 (en) * 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
WO2000032634A1 (fr) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Anticorps anti-interferon gamma humanises
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
WO2000061637A1 (fr) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Anticorps du recepteur d'erythropoietine
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6262247B1 (en) * 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP1433793A4 (fr) * 2001-09-13 2006-01-25 Inst Antibodies Co Ltd Procede pour creer une banque d'anticorps de chameaux
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP1470232A1 (fr) * 2002-01-31 2004-10-27 Oxford Biomedica (UK) Limited Vecteur d'expression de l'erythropoietine physiologiquement regule, destine au traitement de l'anemie
GB0202252D0 (en) * 2002-01-31 2002-03-20 Oxford Biomedica Ltd Anemia
SI1492878T1 (sl) * 2002-03-26 2007-12-31 Lek Pharmaceutical And Chemical Co. D.D. Postopek za pripravo Ĺľelenega profila gliko-izoform eritropoietina
SI1527100T1 (sl) 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
WO2003094858A2 (fr) * 2002-05-13 2003-11-20 Modigenetech Ltd. Érythropoïétine comportant une extension ctp
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
US20040071694A1 (en) * 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
CN1173737C (zh) * 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
CA2522680A1 (fr) * 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Gene d'hemochromatose juvenile (hfe2a), produits d'expression et leurs utilisations
ATE478093T1 (de) * 2003-05-12 2010-09-15 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
NZ543905A (en) * 2003-05-12 2008-07-31 Affymax Inc Peptides that bind to the erythropoietin receptor
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
KR20060032140A (ko) 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20050019914A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005012538A2 (fr) * 2003-08-01 2005-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccination acceleree
DE10349124A1 (de) * 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
ES2445948T3 (es) * 2003-11-24 2014-03-06 Ratiopharm Gmbh Eritropoyetina glicopegilada
WO2005065239A2 (fr) 2003-12-31 2005-07-21 Centocor, Inc. Nouvelles proteines recombinees avec thiol libre n-terminal
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
US7423139B2 (en) * 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
CA2657307A1 (fr) * 2006-07-21 2008-01-24 Amgen Inc. Procede de detection et/ou de mesure de la concentration d'hepcidine dans un echantillon
AR069062A1 (es) 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098444A2 (fr) * 2001-05-25 2002-12-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de l'hepcidine comme regulateur de l'homeostasie ferrique
WO2004058044A2 (fr) * 2002-11-19 2004-07-15 Drg International, Inc. Methode diagnostique pour maladies par criblage d'hepcidine dans des tissus, du sang ou des fluides corporels humains ou animaux et utilisations therapeutiques
WO2004106362A2 (fr) * 2003-05-30 2004-12-09 Cellpep S.A. Oxydation de peptides
US20060019339A1 (en) * 2004-04-28 2006-01-26 Xavier Lauth Measurement of bioactive hepcidins
WO2006099126A2 (fr) * 2005-03-11 2006-09-21 Ciphergen Biosystems, Inc. Biomarqueurs du cancer de l'ovaire et de l'endometre: la hepcidine
WO2008089795A1 (fr) * 2007-01-25 2008-07-31 Drg International, Inc. Procédé de diagnostic de maladies par dépistage de l'hepcidine dans des tissus, du sang ou des liquides organiques humains ou animaux, anticorps monoclonaux spécifiques de l'hepcidine humaine et leurs utilisations associées

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HUNTER HOWARD N ET AL: "The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 40, 4 October 2002 (2002-10-04), pages 37597 - 37603, XP002519930, ISSN: 0021-9258 *
KULAKSIZ H ET AL: "Pro-hepcidin: expression and cell specific localisation in the liver and itsregulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia", GUT, BRITISH MEDICAL ASSOCIATION, LONDON, vol. 53, no. 5, 1 January 2004 (2004-01-01), pages 735 - 743, XP008083550, ISSN: 0017-5749 *
NEMETH ELIZABETA ET AL: "The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study", BLOOD, vol. 107, no. 1, January 2006 (2006-01-01), pages 328 - 333, XP002519931, ISSN: 0006-4971 *
PARK CHRISTINA H ET AL: "Hepcidin, a urinary antimicrobial peptide synthesized in the liver", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 276, no. 11, 16 March 2001 (2001-03-16), pages 7806 - 7810, XP002211393, ISSN: 0021-9258 *
SWINKELS D W ET AL: "Hereditary hemochromatosis: genetic complexity and new diagnostic approaches", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, vol. 52, no. 6, 1 June 2006 (2006-06-01), pages 950 - 968, XP008083632, ISSN: 0009-9147 *

Also Published As

Publication number Publication date
PE20090722A1 (es) 2009-07-13
EP2111412A2 (fr) 2009-10-28
WO2008097461A2 (fr) 2008-08-14
AR065083A1 (es) 2009-05-13
PE20130588A1 (es) 2013-05-21
TW200900420A (en) 2009-01-01
AU2008214386B2 (en) 2013-09-19
US8629250B2 (en) 2014-01-14
US20130018176A1 (en) 2013-01-17
TW201307390A (zh) 2013-02-16
AU2008214386A1 (en) 2008-08-14
TW201206954A (en) 2012-02-16
MX2009008104A (es) 2009-08-07
CL2008000278A1 (es) 2008-09-26
AU2008214386A2 (en) 2009-10-08
JP2010517529A (ja) 2010-05-27
JP2014221763A (ja) 2014-11-27
US20140286953A1 (en) 2014-09-25
CA2676036A1 (fr) 2008-08-14
US20080213277A1 (en) 2008-09-04
AR082235A2 (es) 2012-11-21

Similar Documents

Publication Publication Date Title
WO2008097461A3 (fr) Hepcidine, antagonistes de l'hepcidine, et procédés d'utilisation
WO2007133290A8 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2008060705A3 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2006028936A3 (fr) Molecules heteromultimeriques
WO2007127317A3 (fr) Anticorps c-kit humanisé
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2007033230A3 (fr) Formulations d'anticorps anti-cd3
WO2009052431A3 (fr) Agents de liaison au cd19 et utilisations de ceux-ci
WO2009002947A3 (fr) Composés et peptides de liaison au récepteur de trail
WO2008121767A3 (fr) Polypeptides cousus
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
WO2008099178A3 (fr) ÉLÉMENTS DE LIAISON POUR MOLÉCULES IgE
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
GB2468232A (en) Antigen-bindng constructs
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
IL204542A (en) Unique monoclonal antibodies for protofibrillary form of cellulose-amyloid protein, methods and uses thereof
WO2008112192A3 (fr) Anticorps epha3 utilises dans le traitement des tumeurs solides
WO2006096489A3 (fr) Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits
WO2012007880A3 (fr) Molécules de liaison à un antigène à domaine unique modifiées et leurs utilisations
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
WO2008151819A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
WO2010136483A3 (fr) Protéines de liaison à l'antigène
WO2008027600A3 (fr) Compositions d'imatinib

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008214386

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2676036

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/008104

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009548312

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008214386

Country of ref document: AU

Date of ref document: 20080130

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008725041

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08725041

Country of ref document: EP

Kind code of ref document: A2